Patients who received durvalumab had numerically higher pCR rates when tumours were PD-L1-positive compared to PD-L1-negative (58.0% versus 44.4%, respectively, p = 0.445); however, this difference was not statistically significant. The gene discussed is CD274; the disease is neoplasm.